ClostraBio

About:

ClostraBio is a biopharma company developing therapeutics for food allergies.

Website: http://www.clostrabio.com

Twitter/X: clostrabio

Top Investors: University of Chicago, Portal Innovations, Joseph Mansueto

Description:

ClostraBio develops drugs that can prevent allergic reactions to food. It is dedicated to understanding and treating food allergies and other diseases of the immune system. The company is discovering and developing new therapeutics that modulate the protective ability of the microbe. ClostraBio’s scientific team has made key discoveries that highlight the importance of the intestinal microbiota in regulating allergic sensitization to food. The company is committed to a deeper understanding of the role of intestinal microbes in gut barrier function and determining the mechanisms of barrier protection.

Total Funding Amount:

$7.54M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Chicago, Illinois, United States

Founded Date:

2016-01-01

Founders:

Cathryn R. Nagler, Jeffrey A. Hubbell

Number of Employees:

1-10

Last Funding Date:

2022-09-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai